Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

ut Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation; or Lori Williams of Baylor College ofMedicine, Office of Public Affairs
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/4/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted its seventh abbreviated new ... Administration (FDA) of 2015, which brings the Company,s total ... to twenty-nine. Jason Grenfell-Gardner , President ... current pipeline of twenty-nine submissions, exclusive of our four ...
(Date:9/4/2015)... 04, 2015 ... announced the addition of the "Investigation ... report to their offering. ... repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. As a ... matrix, sodium hyaluronate can lubricate the joint, ...
(Date:9/3/2015)... 2015 Report Details What can ... are going to grow at the fastest rates? Visiongain,s ... assessing data, trends, opportunities and prospects there. ... Discover the most lucrative areas in the industry and ... assess forecasted sales at overall world market and regional ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Investigation Report on China's Sodium Hyaluronate Market 2015 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4
(Date:9/4/2015)... ... September 04, 2015 , ... Georgia Insurance Advisors, a ... charity effort to provide for the family of Grace, a young local girl ... cardiomyopathy often leads to diastolic dysfunction – the inability to adequately move blood ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and ... rules constantly evolving in the consumer goods industry, it can be difficult for ...
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts ... the Year” awards at this year’s Microsoft Worldwide Partner Conference that was held ... the Year” Award Winner for Data Platform services, the 2015 HP and Microsoft ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... ... 04, 2015 , ... Mike Day, a former Navy SEAL who was shot ... World Championships in Kona on October 10th. , Mike is running the race to ... combat and the cutting-edge treatments that restore their quality of life. More ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay News) ... the metal mesh tubes used to keep clogged arteries ... came out on top, South Korean researchers report. ... the study found. Coating stents with time-released drugs ...
... Clinic researchers and their international colleagues have discovered genetic ... of women when taking aromatase inhibitors to treat their ... that many women halt their lifesaving medication. The findings ... of Clinical Oncology . "Many women stop taking ...
... and close friends are more sensitive to early signs ... researchers at Washington University School of Medicine in St. ... having memory problems by testing them with a variety ... words or comparing shapes of objects. Washington University researchers ...
... 2010) Virginia Commonwealth University School of Medicine and ... impotence drug Viagra, in combination with doxorubicin, a powerful ... while alleviating the damage to the heart at the ... decades the chemotherapeutic agent doxorubicin has been used to ...
... - The National Cancer Institute has awarded a five-year, ... at Chapel Hill,s Carolina Center of Cancer Nanotechnology Excellence ... for research to improve the diagnosis and treatment of ... support the continued work of the center launched in ...
... continuing in Afghanistan, UCLA has helped develop a first-of-its-kind ... in critical combat casualty care. The program will not ... but civilian care as well. Based ... Operation Iraqi Freedom and Operation Enduring Freedom in Afghanistan, ...
Cached Medicine News:Health News:In Test of Stents, Old Standby Wins Out 2Health News:Mayo collaboration finds source of breast drug side effect 2Health News:Friends, family detect early Alzheimer's signs better than traditional tests 2Health News:Friends, family detect early Alzheimer's signs better than traditional tests 3Health News:VCU study: Researchers discover a drug combination that shrinks tumors in vivo 2Health News:NCI awards $13.6 million to UNC's Carolina Center of Cancer Nanotechnology Excellence 2Health News:NCI awards $13.6 million to UNC's Carolina Center of Cancer Nanotechnology Excellence 3Health News:UCLA develops combat casualty care educational program for US armed forces 2Health News:UCLA develops combat casualty care educational program for US armed forces 3
... The Polaris system delivers the ... cost effective and easy to use, ... level of precision measurement with unprecedented ... both active and passive tools, the ...
Penfield Dissector #4...
Leroy scalp clips, sterile, disposable, plastic, infant size, ten clips/package....
Disposable scalp clip applier, comes loaded with 12 Leroy-Raney clips, ergonomic, easy to handle and position the clip....
Medicine Products: